Johnson & Johnson Submits Supplemental NDA To U.S. FDA Seeking Expanded Pediatric Indication For HIV-1 Therapy PREZCOBIX
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson has submitted a supplemental New Drug Application (NDA) to the U.S. FDA to expand the pediatric indication for its HIV-1 therapy, PREZCOBIX.
June 04, 2024 | 8:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson has submitted a supplemental NDA to the U.S. FDA to expand the pediatric indication for its HIV-1 therapy, PREZCOBIX. This could potentially increase the market for PREZCOBIX if approved.
The submission of a supplemental NDA to expand the pediatric indication for PREZCOBIX could lead to an increased market size for the drug if approved. This is a positive development for Johnson & Johnson as it could boost revenues from this therapy.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100